CTOs on the Move

RootPath Genomics

www.rootpath.com

 
RootPath, Inc. is a Cambridge, MA-based early-stage biotechnology company focusing on next-generation immuno- and cell-therapy.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

RootPath Genomics raised $11M on 01/05/2020

Similar Companies

SHYFT Analytics

SHYFT has been an integral part of the life sciences ecosystem for over 10 years and as the market undergoes a dramatic transformation to deliver more personalized and value-based medicine, the role of SHYFT has never been more important. We built the SHYFT Platform to help life science companies integrate clinical and commercial data and translate it into patient-centric intelligence and analytics for use across functional groups, shortening development cycles and commercialization activities while improving the probability of success. With a long history of success and deep client partnerships, we understand the market transformation and the actionable intelligence required for successful launch, growth and maintenance of new therapies. At SHYFT, we collaborate with our clients to ensure their success not only today, but in the future by providing flexible, agile solutions based on deep industry expertise. With an impressive customer retention rate, we`re committed to our client`s success and serve as a true partner in the transformation.

Protox Therapeutics Inc

Protox Therapeutics Inc is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aerpio Therapeutics

Aerpio Therapeutics is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector. Aerpio Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye.

Millendo

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing`s Syndrome (CS).

Simplex Sciences

High quality, reliable single-stranded DNA ladders from Simplex Sciences. 10, 20, 50, and 100 base increment ladders are available, with new products coming soon.